Protection Against Insulin Resistance in Obesity

NCT02717832 | Completed Results

• 1 other identifier: HUM00111275
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

The overall goal of this project is to identify factors that "protect" some obese adults from becoming insulin resistant. Identifying mechanisms that help protect some obese adults from developing insulin resistance could lead to novel, targeted therapeutic and/or preventative strategies for obese adults who are insulin resistant.

Conditions

Obesity; Insulin Resistance

Outcome Measures

Primary Outcomes (1)

• Insulin Sensitivity

  A hyperinsulinemic-euglycemic clamp will be used to assess peripheral insulin sensitivity

  baseline (this cross-sectional study involves only one insulin sensitivity measurement in a single visit for each participant)

Secondary Outcomes (1)

• Resting Metabolic Rate

  baseline (this cross-sectional study involves only one Resting Metabolic Rate measurement in a single visit for each participant)

Study Arms (1)

Insulin Sensitivity

EXPERIMENTAL

Drug: hyperinsulinemic-euglycemic clamp

Interventions

hyperinsulinemic-euglycemic clamp DRUG

Insulin Sensitivity

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Body mass index \[BMI\]: 30-40 kg/m2
• Age: 18-45 years
• All women must be pre-menopausal
• Non-exerciser: no regularly planned exercise/physical activity

You may not qualify if:

• Weight instability ≥ ±3kg ≥ 6 months
• Medications known to affect lipid and/or glucose metabolism
• Pregnancy or actively breast feeding

Sponsors & Collaborators

• University of Michigan: lead

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Obesity; Insulin Resistance

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases

Results Point of Contact

• Title: Dr. Jeffrey Horowitz
• Organization: University of Michigan

jeffhoro@umich.edu

734-647-1076

Study Officials

• Jeffrey F Horowitz

  University of Michigan

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Movement Science and Director, Substrate Metabolism Laboratory

Study Record Dates

• First Submitted: March 7, 2016
• First Posted: March 24, 2016
• Study Start: March 1, 2016
• Primary Completion: August 9, 2019
• Study Completion: August 9, 2019
• Last Updated: May 11, 2022
• Results First Posted: May 11, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)